Showing results (121-130 of 242) with videos related to

Sort By:
Pageof 25
Nature Reviews. Urology|July 31, 2013
How 'male health' fits into the field of urologyDean S Elterman, Steven A Kaplan, Richard S Pelman, et al.
BJU International|October 5, 2011
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptomsSteven A Kaplan, Claus G Roehrborn, Jason Gong, et al.
Urology|November 8, 2011
Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) studyKarin S Coyne, Mary Kay Margolis, Zoe S Kopp, et al.
The Aging Male : the Official Journal of the International Society for the Study of the Aging Male|March 14, 2013
Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS)Steven A Kaplan, Edward O'Neill, Robert Lowe, et al.
BJU International|May 5, 2018
Factors influencing long-term urinary symptoms after prostate brachytherapyNelson N Stone, Jared S Winoker, Steven A Kaplan, et al.
Advances in Therapy|June 30, 2026
Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative ReviewBradley C Gill, Matt T Rosenberg, Steven A Kaplan, et al.
The Journal of Urology|February 22, 2011
Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trialSteven A Kaplan, Jeannette Y Lee, Alan G Meehan, et al.
Reviews in Urology|November 14, 2013
Use of herbal supplements for overactive bladderBilal Chughtai, Elizabeth Kavaler, Richard Lee, et al.
The Journal of Urology|September 17, 2004
Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trialAlexis E Te, Terrence R Malloy, Barry S Stein, et al.
BJU International|September 24, 2010
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trialSteven A Kaplan, Tim Schneider, Jenelle E Foote, et al.
Pageof 25